Latest studies
- Active not recruitingPHASE3
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study looked at new ways to treat a type of lung cancer called extensive-stage small cell lung cancer (ES-SCLC). It compared a combination of medicines with standard chemotherapy to see if it could help people live longer. The study was changed partway through, so the focus shifted.
Small Cell Lung CarcinomaLithuania - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisLithuania - Active not recruitingPHASE3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study looks at a new medicine called sparsentan for IgA nephropathy (IgAN), a kidney disease. It compares sparsentan to a standard treatment (irbesartan) to see if it helps protect kidneys and reduce protein in the urine over about two years.
Immunoglobulin A NephropathyLithuania - RecruitingPHASE3
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
This study looks at a medicine called vedolizumab for children and teenagers with moderate to severe Crohn's disease. It aims to see if the medicine can make their symptoms better and heal inflammation in their gut.
Crohn's Disease (CD)Lithuania - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseLithuania - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseLithuania - RecruitingPHASE3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Duvakitug for people with Crohn's disease that isn't well controlled. It compares Duvakitug to a dummy medicine to see if it's safe and effective in improving symptoms for those with moderately to severely active Crohn's.
Crohn's DiseaseLithuania - Active not recruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
This study looks at a new medicine called lutikizumab for adults with moderate to severe ulcerative colitis. It aims to see if it's safe and how well it works compared to a common treatment called adalimumab.
Ulcerative ColitisLithuania - Active not recruitingPHASE3
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study is looking at a new medicine called vutrisiran for people with a heart condition called transthyretin amyloidosis (ATTR) cardiomyopathy. It aims to see if the medicine can help improve the condition and if it's safe compared to a dummy treatment.
Transthyretin Amyloidosis (ATTR) With CardiomyopathyLithuania - RecruitingPHASE2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
This study is testing a new drug, SAB-142, for people with recently diagnosed Type 1 Diabetes. It aims to see if SAB-142 can slow down the disease, and if it's safe to use. Participants will receive high dose, low dose, or a dummy drug.
Type 1 DiabetesLithuania - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseLithuania - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic NeoplasmsLithuania - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
This study compares two medicines, crovalimab and eculizumab, for a rare blood condition called PNH. It's for people who haven't tried these types of medicines before, checking if crovalimab works as well and is as safe as eculizumab.
Paroxysmal Nocturnal HemoglobinuriaLithuania - RecruitingPHASE3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
This study looks at how safe a new medicine called finerenone is for children and young people (aged 1-18) with long-term kidney disease, when taken with other common kidney medicines. It also checks if it helps reduce protein in their urine.
Chronic Kidney DiseaseProteinuriaChildrenLithuania - RecruitingPHASE3
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
This study compares a new treatment combining petosemtamab and pembrolizumab with pembrolizumab alone for advanced head and neck cancer. It aims to see if the combination works better and is safe for patients whose cancer has come back or spread.
Head and Neck Squamous Cell CarcinomaLithuania - RecruitingPHASE3
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
This study is looking at a new treatment called petosemtamab for advanced head and neck cancer. It compares this new drug with standard treatments chosen by doctors, for patients whose cancer has come back or spread after previous therapies.
Head and Neck Squamous Cell CarcinomaLithuania - Active not recruitingPHASE3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
This study is for men with cancer who are already taking darolutamide in another Bayer study and are doing well. It lets them keep taking the same medicine at the same dose, continuing their treatment journey under medical supervision.
CancerLithuania - Active not recruitingPHASE3
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
This study is testing a new combination treatment for advanced bowel cancer. It compares a new medicine (S95005) with an existing one (capecitabine), both given with bevacizumab. The aim is to see if the new combination works better for patients who can't have intensive chemotherapy.
Metastatic Colorectal CancerLithuania - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseLithuania - Active not recruitingPHASE3
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study looks at a new medicine called concizumab for people with haemophilia A or B without inhibitors. It aims to see how well it prevents bleeding and if it's safe. Participants will take the medicine daily, usually by injection under the skin, for up to 8 years.
Haemophilia A Without InhibitorsHaemophilia B Without InhibitorsLithuania - Active not recruitingPHASE3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
This study compares a new medicine, risankizumab, with a dummy treatment (placebo) for people with active psoriatic arthritis. It checks how safe and effective risankizumab is, especially for those who haven't responded well to other treatments.
Psoriatic ArthritisLithuania - RecruitingPHASE2, PHASE3
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
This study is looking into a new medicine called efgartigimod for young people aged 12 to 17 with a blood condition called chronic ITP. The aim is to find the best dose to help increase their platelet count and manage their condition.
Immune Thrombocytopenia (ITP)ITP - Immune ThrombocytopeniaITPImmune Thrombocytopenic PurpuraLithuania - Active not recruitingPHASE3
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
This study looks at the long-term safety and effects of a medicine called iptacopan for people with a rare blood condition called PNH. It's for patients who have already been taking iptacopan in other studies and found it helpful, to make sure they can continue treatment safely.
Paroxysmal Nocturnal HemoglobinuriaLithuania - Active not recruitingPHASE3
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
This study looks at the long-term safety of a new medicine, itepekimab, for people with severe lung disease (COPD). It will also check if the medicine continues to help over time. Participants will have already been part of a previous study on this medicine.
Chronic Obstructive Pulmonary DiseaseLithuania - Active not recruitingPHASE3
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
This study looks at new ways to treat advanced lung cancer that can't be removed by surgery. It combines standard chemotherapy and radiation with newer drugs, pembrolizumab and olaparib, to see if they can improve survival compared to current treatments.
Lung NeoplasmsCarcinoma, Non-Small-Cell LungLithuania - Active not recruitingPHASE3
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
This study looks at the long-term safety and effectiveness of a new medicine, ianalumab, for people with Sjögren's Syndrome. It's for those who have already completed an earlier study and aims to see how well the treatment works and if it has any long-term side effects.
Sjogrens SyndromeLithuania - Active not recruitingPHASE3
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
This study looks at new drug combinations for a type of lung cancer called Limited-Stage Small Cell Lung Cancer (LS-SCLC). Researchers want to see if adding pembrolizumab and olaparib to standard treatments helps people live longer.
Small Cell Lung CancerLithuania - Active not recruitingPHASE2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
This study is testing a new medicine, Verekitug, for people with moderate to severe COPD. It will check how well the medicine works and if it's safe. Participants will take Verekitug or a dummy pill alongside their usual COPD treatments.
Chronic Obstructive Pulmonary DiseaseLithuania - RecruitingPHASE3
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
This study compares Elritercept with Epoetin Alfa for adults with a certain type of Myelodysplastic Syndrome (MDS) and anaemia. It checks if Elritercept reduces the need for blood transfusions and improves tiredness, while also looking at safety.
Myelodysplastic SyndromeAnemiaLithuania - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative ColitisLithuania - Active not recruitingPHASE3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This study looks at the long-term safety and effectiveness of a medicine called ocrelizumab for people with Multiple Sclerosis (MS). It's for people already taking part in other ocrelizumab studies, to see how the treatment works over a longer time.
Multiple SclerosisLithuania - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
High-Risk NeuroblastomaPatient With Insufficient Response ChemoimmunotherapyLithuania - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
This study is looking into a new medication called remibrutinib for people with a type of multiple sclerosis (MS) called Secondary Progressive MS (SPMS). It will check if the medicine is safe and helps slow down the disease.
Secondary Progressive Multiple Sclerosis (SPMS)Lithuania - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
This study is testing a new medicine, Debio 4126, for people with acromegaly, a hormone disorder, who are already taking similar treatments. We want to see if Debio 4126 can help keep their hormone levels stable compared to a dummy drug.
AcromegalyLithuania - Active not recruitingPHASE3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.
Multiple SclerosisLithuania - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This study aims to see if adding the drug pembrolizumab to standard chemotherapy before and after surgery helps people with early-stage non-small cell lung cancer live longer and prevent the cancer from returning. It's a large study comparing this new approach with chemotherapy alone.
Non-small Cell Lung CancerLithuania - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseLithuania - Active not recruitingPHASE3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
This study looks at a new medicine called ziltivekimab for people with heart failure and inflammation. It aims to see if monthly injections of ziltivekimab can help, compared to a dummy medicine, over a few years.
Heart FailureLithuania - Active not recruitingPHASE3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This study looks at the everyday safety and how well a drug called tolebrutinib is tolerated over a long time. It's for adults with different types of multiple sclerosis (MS) who have already been in earlier tolebrutinib studies.
Relapsing Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple SclerosisLithuania - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
This study looks at the long-term safety and effectiveness of a medicine called Upadacitinib for people with ulcerative colitis. It's for those who haven't fully responded to previous treatment or have completed an earlier study.
Ulcerative Colitis (UC)Lithuania - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesLithuania - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesLithuania - Active not recruitingPHASE4
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
This study compares two treatments, Radium-223 (Xofigo) and ARPI therapy, for prostate cancer that has spread to the bones. It aims to see which is more effective and safer for men who have already tried ARPIs.
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Lithuania - RecruitingPHASE3
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
This study looks at the long-term safety of a medicine called vedolizumab for children and young people with Crohn's disease or ulcerative colitis. It's for those who have already taken part in a previous study with vedolizumab.
Ulcerative ColitisCrohn's DiseaseLithuania - Active not recruitingPHASE3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
This study looks at a new tablet treatment, upadacitinib, for adults with moderate to severe lupus. It checks how safe and effective the medicine is and aims to reduce symptoms. Some people will get the active drug, others a dummy pill.
Systemic Lupus ErythematosusLithuania - RecruitingPHASE3
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
This study is looking into a new treatment called brenetafusp, combined with nivolumab, for advanced melanoma. We're comparing it to current standard nivolumab treatments to see if it works better for people in the UK whose melanoma hasn't been treated before.
Advanced MelanomaLithuania - Enrolling by invitationPHASE3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study looks at a new treatment called Selatogrel for people who have recently had a heart attack and are at risk of another. It checks if taking Selatogrel when symptoms start can help prevent a second heart attack.
Acute Myocardial InfarctionLithuania - Active not recruitingPHASE3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
This study looks at a new drug, isatuximab, combined with standard treatments (lenalidomide and dexamethasone) for people with high-risk smoldering multiple myeloma. It aims to see if this combination can prevent the disease from getting worse compared to the standard treatments alone.
Plasma Cell MyelomaLithuania - Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
Crohn's DiseaseLithuania - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisLithuania